University of Rochester James P Wilmot Cancer Institute
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipe, Brea
NCT03839459: Denosumab for Smoldering Multiple Myeloma

Active, not recruiting
2
20
US
Denosumab
University of Rochester, Amgen
Smoldering Multiple Myeloma
09/22
06/25
NCT02833610: A Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency

Completed
2
55
US
Denosumab Q4W, Xgeva, Prolia
Massachusetts General Hospital, Amgen, Emory University, University of Rochester, University Hospitals Cleveland Medical Center
Multiple Myeloma
03/23
03/23
NCT04140162: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Active, not recruiting
2
57
US
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Multiple Myeloma
05/24
05/26
NCT05597345: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Recruiting
2
15
US
Selinexor
University of Rochester, Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
12/24
12/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Hourglass Feb 2024 - Dec 2024 : Results from STOMP trial for RRMM and NDMM
Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with lenalidomide and dexamethasone for multiple myeloma at ASH 2020
More
Recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
SGNBCMA-001, NCT03582033: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Terminated
1
83
US
SEA-BCMA, dexamethasone, pomalidomide
Seagen Inc.
Multiple Myeloma
11/23
11/23
Burrows, Kaitlyn
MB106-CD20-001, NCT05360238: Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Terminated
1/2
20
US
MB-106
Mustang Bio, National Cancer Institute (NCI)
Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory, Chronic Lymphoid Leukemia in Relapse, B-cell Lymphoma Refractory
04/24
04/24

Download Options